Keros Therapeutics, Inc. (KROS)
NASDAQ: KROS · Real-Time Price · USD
10.03
-0.27 (-2.62%)
At close: Nov 16, 2026, 4:00 PM EST
10.18
+0.15 (1.50%)
After-hours: Nov 16, 2026, 7:30 PM EST

Keros Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
40.76244.063.550.15-20.1
Revenue Growth
-83.48%6774.96%2250.99%---
Cost of Revenue
74.33127.14173.63135.2687.2755.14
Gross Profit
-33.57116.92-170.08-135.11-87.27-35.04
Selling, General & Admin
36.746.3540.7534.8327.5321.33
Operating Expenses
36.746.3540.7534.8327.5321.33
Operating Income
-70.2770.57-210.83-169.94-114.79-56.37
Interest Expense
-----0-0
Interest & Investment Income
10.9224.8723.514.763.640.03
Currency Exchange Gain (Loss)
0.42---0.21-0.61-
Other Non Operating Income (Expenses)
-0.54-0.540.282.47.08-0.38
EBT Excluding Unusual Items
-59.4794.9-187.05-152.99-104.68-56.73
Merger & Restructuring Charges
-3-3----
Pretax Income
-62.4791.9-187.05-152.99-104.68-56.73
Income Tax Expense
-0.744.880.3--2.01
Net Income
-61.7387.01-187.35-152.99-104.68-58.74
Net Income to Common
-61.7387.01-187.35-152.99-104.68-58.74
Net Income Growth
------
Shares Outstanding (Basic)
223737292523
Shares Outstanding (Diluted)
223837292523
Shares Change
-47.30%1.13%27.13%16.66%8.17%50.48%
EPS (Basic)
-2.862.34-5.00-5.20-4.15-2.52
EPS (Diluted)
-2.862.30-5.00-5.20-4.15-2.52
EPS Growth
------

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
-48.27105.95-162.8-126.97-71.3-63.17
Free Cash Flow Per Share
-2.232.80-4.35-4.31-2.83-2.71
Gross Margin
-82.36%47.91%----174.34%
Operating Margin
-172.39%28.91%-5938.96%-112543.71%--280.46%
Profit Margin
-151.43%35.65%-5277.55%-101319.21%--292.26%
Free Cash Flow Margin
-118.43%43.41%-4585.91%-84087.42%--314.29%
EBITDA
-68.6872.08-209.6-169.13-114.12-56
EBITDA Margin
-168.49%29.53%----278.58%
D&A For EBITDA
1.591.511.230.820.670.38
EBIT
-70.2770.57-210.83-169.94-114.79-56.37
EBIT Margin
-172.39%28.91%----280.46%
Effective Tax Rate
-5.31%----
Revenue as Reported
40.76244.063.550.15-20.1
SEC Filings: 10-K · 10-Q